The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.

Accelerating the Development and Delivery of

Effective Oncology Treatments

to Patients

 

Cancer Drug Development Forum (CDDF) is a neutral, non–competitive platform

for multi-stakeholder discussions and collaboration in the development of cancer drugs.

 

Unique Multi-Stakeholder Platform

Patients are the cornerstone of CDDF’s mission and central to our multi-stakeholder discussions. Patients and advocacy groups are invited to join the CDDF multi-stakeholder community and make their voices heard. Check out collaborative opportunities and grants available to patients.

The CDDF provides the healthcare industry with unique opportunities to collaborate with diverse stakeholders and take part in open dialogue to accelerate oncology drug development. Discover the CDDF Industry Membership Program and engage with key experts in oncology.

The CDDF fosters advancement and innovation in cancer research by creating a collaborative platform for academics to share knowledge and expertise with a multi-stakeholder audience. Join CDDF’s discussions on the latest developments and explore opportunities to contribute.

The CDDF convenes discussions on key topics in oncology, fostering a balanced exchange of perspectives. Regulators and HTA agencies can gain valuable insights and stay informed on emerging trends through our productive dialogue. Explore collaboration opportunities and join our community.

CANCER DRUG DEVELOPMENT FORUM

The leading non-competitive drug development platform working to stimulate the advancement and accessibility of cancer treatment.

ACT EU Multi-Stakeholder Platform: Meeting Documents from 18 June 2026

The meeting documents from ACT-EU MSP meeting held on 18 June 2026 are available now on the ACT EU website. These include presentations from the European Commission on Progress with the BioTech Act and specifically its clinical trial related aspects - present by C....

Report on the ACT EU Webinar Regarding Contractual Agreements

The report on the ACT EU webinar regarding contractual agreements, held on 16 April, has been published on the ACT EU website. The webinar explored how clinical site agreements affect the start-up of clinical trials and shared national and European experiences on...

Final: ICH E6(R3) GCP Annex 2

📢 ICH E6(R3) GCP Annex 2 was finalized and published by ICH on 3 June 2026. It covers pragmatic and decentralized elements, as well as the use of real-world data (RWD)—topics frequently discussed in CDDF meetings. The guidance also offers valuable insights into...

Key Takeaways from CDDF Live Webinar Series – “AI and Big Data AI in Drug Development: Transparency and Risk Assessment” (16 June 2026)

The CDDF is pleased to share the key takeaways from our live webinar series – “AI and Big Data AI in Drug Development: Transparency and Risk Assessment” held on 16 June 2026. This webinar included a lecture by Dr. Weida Tong  (FDA) followed by a 30-minute Q&A...

[MESSAGE FROM ACT EU – Request for stakeholders’ input on the guideline to simplify the clinical trials application package for use during Public Health Emergencies (PHEs).]

ACT EU has developed the guideline to simplify the clinical trials application package for use during PHEs. The package consists of: 1️⃣ A guidance document on the simplified application package for clinical trials targeting a PHE 2️⃣ Annex I: Part I language...

CDDF’s New Board Announcement: Welcoming Dr. Agnes Saint-Raymond and Ms. Jana Pelouchova

🔔📢 CDDF’s New Board Announcement: Welcoming Dr. Agnes Saint-Raymond and Ms. Jana Pelouchova The Cancer Drug Development Forum (CDDF) is pleased to announce the appointment of Dr. Agnes Saint-Raymond and Ms. Jana Pelouchova to its Board of Directors. We look forward to...

Key Takeaways from CDDF Live Webinar Series – “AI and Big Data AI in Drug Development: Use of AI in Clinical Trials” (12 May 2026)

The CDDF is pleased to share the key takeaways from our live webinar series – “AI and Big Data AI in Drug Development: Use of AI in clinical trials” held on 12 May 2026. This webinar included a lecture by Dr. James Gulley (NIH) followed by a 30-minute Q&A...

[ACT EU Workplan for 2026-2027 – Version 4, May 2026]

The ACT EU workplan for 2026 – 2027 has been adopted by the ACT EU Steering Group and is now published. The workplan reflects the revised ACT EU objectives and takes into account recent legislative and policy developments including the proposed Biotech Act, the...

Executive Summary: CDDF & AAADV Workshop – Challenges in the Landscape of a Global Development Strategy Including Patient Access (30-31 March 2026, BE)

The Cancer Drug Development Forum (CDDF) is delighted to announce that the executive summary of the CDDF & AAADV joint workshop on “Challenges in the Landscape of a Global Development Strategy Including Patient Access” has been published today. This...

[News from ACT EU] – Clinical Trials Information System (CTIS): training and support

Check out the publication of a new EMA document of frequently asked questions (FAQ) for sponsors on the Clinical Trials Information System (CTIS):...

CDDF Webinar: AI and Big Data AI in Drug Development: Transparency and Risk Assessment (June 2026)

The recording of the recent CDDF webinar on “AI and Big Data AI in Drug Development: Transparency and Risk Assessment” is available here. Enjoy the insightful talk from Dr. Weida Tong (FDA) followed by an interactive Q&A session.

CDDF & Oncology News

Check out the recent updates within the CDDF and the latest news in the community of cancer research

CDDF Brochure

Access the CDDF Brochure here

 

Join the CDDF community to find ways to accelerate oncology drug development and deliver optimal treatment to cancer patients

COLLABORATION IS THE KEY

TO IMPROVING OUTCOMES

FOR CANCER PATIENTS

Cancer Drug Development Forum asbl
Registered office: c/o BLSI, Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium
Register of legal entities: the French Speaking Enterprise Court in Brussels
Enterprise number: 738.523.752

Privacy Policy

info@cddf.org
Tel: +32 2 880 62 70